Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Conditions

• Atopic Dermatitis

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Key Dates

Start date

Jul 14, 2025

Status verified

Nov 2025

Primary completion

Nov 6, 2026

Completion

Nov 30, 2027

Study Design

Enrollment

1,000 participants (estimated)

Arms

• Arm: Nemolizumab
  Participants with moderate-to-severe AD who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.

Primary Outcome Measure

Investigator Global Assessment (IGA) at Month 6 [ Time Frame: At Month 6 ]

Central Contacts

• Galderma Research and Development
  817-961-5000
  [email protected]

Locations (59)

Find similar trials in Birmingham, AL

Related Studies

• Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Studies of Skin Microbes in Healthy People and in People With Skin Conditions
  Recruiting · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland
• Natural History and Genetics of Food Allergy and Related Conditions
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
  Recruiting · Regeneron Pharmaceuticals · Boston, Massachusetts